HDAC6 inhibitor accelerates wound healing by inhibiting tubulin mediated IL-1β secretion in diabetic mice.
Animals
Blotting, Western
Endotoxemia
/ chemically induced
Enzyme Inhibitors
/ therapeutic use
Glucose
/ metabolism
Histone Deacetylase 6
/ antagonists & inhibitors
Hydroxamic Acids
/ therapeutic use
Immunohistochemistry
Indoles
/ therapeutic use
Interleukin-10
/ metabolism
Interleukin-1beta
/ metabolism
Lipopolysaccharides
/ pharmacology
Macrophages
/ drug effects
Male
Mice
Mice, Inbred C57BL
Nocodazole
/ pharmacology
RAW 264.7 Cells
Real-Time Polymerase Chain Reaction
Diabetic wounds
HDAC6
IL-10
IL-1β
Macrophages
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
15
11
2019
revised:
18
07
2020
accepted:
20
07
2020
pubmed:
28
7
2020
medline:
15
12
2020
entrez:
27
7
2020
Statut:
ppublish
Résumé
Delayed wound healing in diabetes is characterized by sustained activation of inflammasome and increased expression of IL-1β in macrophages. Identification and validation of novel pathways to regulate IL-1β expression will provide therapeutic targets for diabetic wounds. Here we report sustained over-expression of histone deacetylase 6 (HDAC6) in wounds of diabetic mice and its role in delayed wound healing. Topical application of HDAC6 inhibitor; Tubastatin A (TSA) gel promoted the wound healing in diabetic mice. TSA hydrogel reduced the infiltration of neutrophils, T-cells and macrophages in the early phase of wound healing. TSA treatment promoted the wound healing by inducing collagen deposition, angiogenesis (CD31) and fibrotic factors (TGF-β1) in the late phase of healing. Protein analysis of the diabetic wounds treated with TSA showed increased acetylated α-tubulin and decreased levels of mature IL-1β with no significant effect on the expression of pro-IL-1β, pro-caspase-1 and active caspase-1. In in vitro assays, macrophages exhibited upregulation of HDAC6, IL-1β and downregulation of IL-10 upon stimulation with high glucose and LPS. TSA inhibited the IL-1β secretion and promoted IL-10 in stimulated macrophages with high glucose and LPS. Further investigations showed that TSA inhibits IL-1β release by inhibiting tubulin dependent lysosomal exocytosis without affecting its transcription and maturation. Nocodazole (known acetylation inhibitor) pre-treatment inhibited TSA effect on IL-1β secretion in high glucose stimulated macrophages. Overall, our findings indicate that sustained HDAC6 expression in diabetic wounds contributes to impaired healing responses and HDAC6 may represent a new therapeutic target for diabetic wounds.
Identifiants
pubmed: 32712153
pii: S0925-4439(20)30251-9
doi: 10.1016/j.bbadis.2020.165903
pii:
doi:
Substances chimiques
Enzyme Inhibitors
0
Hydroxamic Acids
0
Indoles
0
Interleukin-1beta
0
Lipopolysaccharides
0
Interleukin-10
130068-27-8
tubastatin A
2XTSOX1NF8
Hdac6 protein, mouse
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Glucose
IY9XDZ35W2
Nocodazole
SH1WY3R615
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165903Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest With the submission of this manuscript we would like to undertake that the above mentioned manuscript has not been published elsewhere, accepted for publication elsewhere or under editorial review for publication elsewhere; and that my Institute's BITS-Pilani, Hyderabad campus and co-authors are fully aware of this submission. The authors declare no conflicts of interest.